RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
HUTCHMED (China) Stock

HUTCHMED (China) Revenue 2025

HUTCHMED (China) Revenue

724.74 M USD

Ticker

13.HK

ISIN

KYG4672N1198

WKN

A2PJ5B

In 2025, HUTCHMED (China)'s sales reached 724.74 M USD, a 15% difference from the 630.2 M USD sales recorded in the previous year.

The HUTCHMED (China) Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2030e1.9214,62
2029e1.7416,13
2028e1.0826,00
2027e1.0227,66
2026e0.8732,37
2025e0.7238,82
20240.6344,64
20230.8454,12
20220.4327,04
20210.3627,49
20200.2317,31
20190.221,84
20180.2132,77
20170.2427,11
20160.2227,65
20150.1837,84
20140.0932,61
20130.0551,74
20120.249,13
20110.1755,60
20100.1359,41
20090.1159,82
20080.0958,39
20070.0757,60
20060.0659,30
20050.0461,21

HUTCHMED (China) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into HUTCHMED (China), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by HUTCHMED (China) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects HUTCHMED (China)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of HUTCHMED (China). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into HUTCHMED (China)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing HUTCHMED (China)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on HUTCHMED (China)’s growth potential.

HUTCHMED (China) Revenue, EBIT and net profit per share

DateHUTCHMED (China) RevenueHUTCHMED (China) EBITHUTCHMED (China) Net Income
2030e1.92 B undefined0 undefined0 undefined
2029e1.74 B undefined521.83 M undefined0 undefined
2028e1.08 B undefined202.01 M undefined190.77 M undefined
2027e1.02 B undefined139.43 M undefined182.14 M undefined
2026e869.04 M undefined50.32 M undefined115.95 M undefined
2025e724.74 M undefined22.52 M undefined406.3 M undefined
2024630.2 M undefined-43.71 M undefined37.73 M undefined
2023838 M undefined18.38 M undefined100.78 M undefined
2022426.41 M undefined-407.69 M undefined-360.84 M undefined
2021356.13 M undefined-328.32 M undefined-194.65 M undefined
2020227.98 M undefined-196.67 M undefined-125.73 M undefined
2019204.89 M undefined-146.39 M undefined-106.02 M undefined
2018214.11 M undefined-92.64 M undefined-74.81 M undefined
2017241.2 M undefined-53.42 M undefined-26.74 M undefined
2016216.08 M undefined-46.7 M undefined11.7 M undefined
2015178.2 M undefined-9.77 M undefined-35.01 M undefined
201487.33 M undefined-18.26 M undefined-32.82 M undefined
201346 M undefined-1 M undefined5.9 M undefined
2012195.4 M undefined-1.3 M undefined3.6 M undefined
2011166.9 M undefined5.2 M undefined700,000 undefined
2010134.5 M undefined-3.1 M undefined-6.9 M undefined
2009111 M undefined-5.6 M undefined-8.7 M undefined
200887 M undefined-15.4 M undefined-17.8 M undefined
200765.1 M undefined-9.7 M undefined-17.2 M undefined
200657.5 M undefined-8.2 M undefined-9.6 M undefined
200537.9 M undefined-6.2 M undefined-6.8 M undefined

HUTCHMED (China) stock margins

The HUTCHMED (China) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HUTCHMED (China). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HUTCHMED (China).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the HUTCHMED (China)'s sales revenue. A higher gross margin percentage indicates that the HUTCHMED (China) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the HUTCHMED (China)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the HUTCHMED (China)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the HUTCHMED (China)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the HUTCHMED (China). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the HUTCHMED (China)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

HUTCHMED (China) Margin History

HUTCHMED (China) Gross marginHUTCHMED (China) Profit marginHUTCHMED (China) EBIT marginHUTCHMED (China) Profit margin
2030e44.64 %0 %0 %
2029e44.64 %29.92 %0 %
2028e44.64 %18.67 %17.63 %
2027e44.64 %13.71 %17.91 %
2026e44.64 %5.79 %13.34 %
2025e44.64 %3.11 %56.06 %
202444.64 %-6.94 %5.99 %
202354.12 %2.19 %12.03 %
202227.04 %-95.61 %-84.62 %
202127.49 %-92.19 %-54.66 %
202017.31 %-86.27 %-55.15 %
201921.84 %-71.45 %-51.75 %
201832.77 %-43.27 %-34.94 %
201727.11 %-22.15 %-11.08 %
201627.65 %-21.61 %5.41 %
201537.84 %-5.48 %-19.65 %
201432.61 %-20.91 %-37.58 %
201351.74 %-2.17 %12.83 %
201249.13 %-0.67 %1.84 %
201155.6 %3.12 %0.42 %
201059.41 %-2.3 %-5.13 %
200959.82 %-5.05 %-7.84 %
200858.39 %-17.7 %-20.46 %
200757.6 %-14.9 %-26.42 %
200659.3 %-14.26 %-16.7 %
200561.21 %-16.36 %-17.94 %

HUTCHMED (China) Aktienanalyse

What does HUTCHMED (China) do?

Hutchison China MediTech Ltd is a Hong Kong-based company specializing in the development and marketing of innovative medications. It has become a significant player in the Asian pharmaceutical industry since its listing on the London Stock Exchange in 2006. The company was founded in 2000 by a team of pharmaceutical experts and scientists and has since evolved into an independent pharmaceutical company. It focuses on developing medications for cancer and inflammatory diseases, incorporating both Western and Chinese medicine practices. Hutchison China MediTech operates in three divisions: innovation, marketing, and manufacturing. It has various medications in its development pipeline, including cancer drugs such as fruquintinib and surufatinib, as well as an anti-inflammatory medication called Naronaprid. The company's headquarters are in Hong Kong, with subsidiaries in Shanghai, Beijing, and Suzhou. Hutchison China MediTech collaborates closely with universities and research institutions globally to advance the development of new medications. Overall, the company has established itself as a significant player in the Asian pharmaceutical industry, operating in a crucial market for the development of innovative medications. HUTCHMED (China) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding HUTCHMED (China)'s Sales Figures

The sales figures of HUTCHMED (China) originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing HUTCHMED (China)’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize HUTCHMED (China)'s sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in HUTCHMED (China)’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about HUTCHMED (China) stock

How much revenue did HUTCHMED (China) generate this year?

HUTCHMED (China) has achieved a revenue of 724.74 M USD this year.

How much was the turnover of the company HUTCHMED (China) compared to the previous year?

The revenue of HUTCHMED (China) has increased by 15% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of HUTCHMED (China)?

The revenue of HUTCHMED (China) is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of HUTCHMED (China) measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of HUTCHMED (China) so important for investors?

The revenue of HUTCHMED (China) is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does HUTCHMED (China) pay?

Over the past 12 months, HUTCHMED (China) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HUTCHMED (China) is expected to pay a dividend of 0 USD.

What is the dividend yield of HUTCHMED (China)?

The current dividend yield of HUTCHMED (China) is .

When does HUTCHMED (China) pay dividends?

HUTCHMED (China) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of HUTCHMED (China)?

HUTCHMED (China) paid dividends every year for the past 0 years.

What is the dividend of HUTCHMED (China)?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is HUTCHMED (China) located?

HUTCHMED (China) is assigned to the 'Health' sector.

Wann musste ich die Aktien von HUTCHMED (China) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HUTCHMED (China) from 8/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/20/2025.

When did HUTCHMED (China) pay the last dividend?

The last dividend was paid out on 8/20/2025.

What was the dividend of HUTCHMED (China) in the year 2024?

In the year 2024, HUTCHMED (China) distributed 0 USD as dividends.

In which currency does HUTCHMED (China) pay out the dividend?

The dividends of HUTCHMED (China) are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von HUTCHMED (China)

Our stock analysis for HUTCHMED (China) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HUTCHMED (China) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.